Roche rapid test can detect Sars-CoV-2 antibodies, pinpointing cases of infection
Pharmaceutical company Roche has launched a rapid test for the detection of antibodies to Sars-CoV-2 to add a point of care testing solution to the fight against Covid-19, the company said.
The launch is a partnership with SD Biosensor Inc, with whom Roche has a global distribution agreement.
The newly developed rapid antibody test is for use in point-of-care settings and can help healthcare professionals identify patients that have developed antibodies against Sars-CoV-2, indicating prior infection, Roche said.
The test is part of the comprehensive Roche diagnostic portfolio to help healthcare systems combat Covid-19, which also includes molecular, serology and digital solutions, the company said.
The rapid antibody test can be performed by healthcare professionals in a number of settings outside clinical labs and near to the patient. This is beneficial in situations where timely decisions are needed, laboratory Sars-CoV-2 testing is not available, or finger prick sampling is the better option over a venous blood draw.
Thomas Schinecker, CEO of Roche Diagnostics, stated that, “We have a global responsibility to help better manage the Covid-19 health crisis and provide solutions to our patients when and where needed. We are proud to have an antibody test for the point of care now included in our Covid-19 diagnostic portfolio.”
